Oxford Immunotec

What Oxford Immunotec does

Oxford Immunotec is a medical diagnostics company that built its business around the proprietary T-SPOT Technology, an ELISPOT-based platform for measuring T cell immune responses via interferon-gamma release assay (IGRA) methodology. The company's core product, the T-SPOT.TB test (TB.300), detects latent tuberculosis infection with a standardized three-step workflow of cell isolation, washing, and counting that produces reportable results independent of patient cell counts; the adjacent T-SPOT.Flex kit supports research-use T cell monitoring, while the T-Cell Select kit (TSK.910) enables T cell isolation, and the Auto-Pure 10B instrument automates sample processing. The company also operates Oxford Diagnostic Laboratories (ODL), a high-throughput reference lab in Abingdon, UK that processes more than 400 TB samples per day, and has extended the platform into cytomegalovirus (CMV) testing for immunocompromised transplant patients.

The company was founded in 2002 in Abingdon, UK, listed on NASDAQ under OXFD, and was acquired by PerkinElmer in 2022 for approximately $591 million. PerkinElmer subsequently rebranded as Revvity, Inc. in 2023, and the T-SPOT portfolio now operates within Revvity's diagnostics and clinical services divisions, distributed across 40+ countries via direct enterprise sales, regional e-commerce portals, and authorized distributors. Its customer base spans clinical laboratories, pharmaceutical/biotech companies conducting immune monitoring and vaccine research, healthcare professionals managing transplant patients, academic researchers, and contract research organizations, with revenue generated from consumable kit sales, capital instrument placements, and reference laboratory testing services.

Since the Oxford Immunotec brand no longer trades independently, T-SPOT.TB and related products are positioned as one line within Revvity's larger diagnostics franchise, with pricing handled through a quote-based enterprise sales motion and digital promotional channels layered on top via Revvity's e-commerce platform.

Name

Oxford Immunotec

Legal name

Oxford Immunotec Global, Ltd.

Website

https://oxfordimmunotec.com

Company type

Private

Founded year

2000

Operating status

Acquired

Headcount range

101–250 employees

Short description

Oxford Immunotec develops T-SPOT ELISPOT-based diagnostic tests for T cell immune response measurement, serving clinical laboratories, pharmaceutical and biotech firms, healthcare professionals, academic researchers, and CROs across 40+ countries via Revvity's global distribution network.

Ownership category

akta.pro rank

Product category

Infectious Disease Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB)

akta.pro secondary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Infectious disease diagnostics
• Tuberculosis testing
• Cell-mediated immunity assays
• T cell diagnostics
• ELISPOT assay kits

Headquarters

HQ city

Abingdon

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. T-SPOT Diagnostic Products: Sale of T-SPOT assay kits including T-SPOT.TB (TB.300), T-SPOT.Flex (FLEX.24.RUO), and T-Cell Select (TSK.910) for clinical and research applications. Revenue generated from kit sales to clinical laboratories, hospitals, and research institutions.
2. Instrument Sales: Sale of instruments including Auto-Pure 10B for automated sample processing. Hardware instruments are sold as capital equipment purchases or potentially with service agreements.
3. Testing Services (Oxford Diagnostic Laboratories): Oxford Diagnostic Laboratories (ODL) operates as a referral laboratory providing TB testing services using T-SPOT technology. The lab receives over 400 samples per day for TB testing, generating revenue from diagnostic testing services.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Oxford Immunotec develops and sells diagnostic test kits, instruments, and reagents based on its proprietary T-SPOT Technology, an ELISPOT (Enzyme-Linked ImmunoSpot) platform that measures T cell immune responses using interferon-gamma release assay (IGRA) methodology. Its core commercial product is the T-SPOT.TB test for tuberculosis detection, supplemented by T-SPOT.Flex research kits, T-Cell Select cell isolation kits, and the Auto-Pure 10B automated instrument. The company also operates Oxford Diagnostic Laboratories (ODL), a UK reference laboratory providing centralized TB testing services processing over 400 samples per day.

Product overview

Oxford Immunotec's T-SPOT portfolio, now part of Revvity following acquisition, consists of a unified platform-plus-products architecture centered on ELISPOT technology for T cell immune response measurement. The core T-SPOT Technology platform provides the foundational IGRA methodology for detecting cell-mediated immunity. This platform supports diagnostic test products including T-SPOT.TB (TB.300) for tuberculosis detection, T-SPOT.Flex (FLEX.24.RUO) for research applications, and T-Cell Select (TSK.910) for cell isolation. Workflow automation is enabled through the Auto-Pure 10B instrument for automated sample processing. Clinical testing services are provided through Oxford Diagnostic Laboratories (ODL). The product ecosystem spans from cell isolation through automated analysis, with the T-SPOT technology serving as the common methodological foundation across all offerings.

Differentiator

Problem solved

Functional benefit

Brands

• T-SPOT Technology: ELISPOT-based platform for measuring T cell immune responses, including the T-SPOT.TB test for tuberculosis detection and T-SPOT.Flex for research applications.
• Oxford Diagnostic Laboratories (ODL)

Products and services

• T-SPOT.TB (TB.300)

Quantifiable outcome

• 400+ samples per day processed through Oxford Diagnostic Laboratories
• +1 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Abbott: Abbott is a major IVD incumbent with ARCHITECT and other immunoassay platforms serving clinical labs worldwide, providing competing TB and infectious disease diagnostic solutions for the same hospital and reference lab customers.
• Thermo Fisher Scientific: Thermo Fisher is a global diagnostics and life sciences incumbent offering immunoassays, clinical lab services, and research reagents, serving the same clinical lab and pharma/biotech customers as Oxford Immunotec's T-SPOT portfolio.
• Bio-Techne: Bio-Techne is a large life sciences tools incumbent offering immunoassay kits, ELISpot reagents, and cytokines under the R&D Systems and Tocris brands, with overlapping research customer bases to Oxford Immunotec's T-SPOT.Flex.
• Roche Diagnostics: Roche Diagnostics is a global IVD incumbent serving clinical laboratories with a broad infectious disease and immunoassay portfolio, including TB testing solutions competing with T-SPOT.TB in large hospital networks.
• Hologic: Hologic is a diagnostics-focused incumbent offering molecular and immunoassay platforms for infectious disease, including TB testing capabilities that overlap with Oxford Immunotec's clinical laboratory customer segments.
• Becton Dickinson (BD): BD is a major diagnostics and life sciences incumbent with flow cytometry and immunology assay platforms serving clinical labs and research institutions, overlapping with Oxford Immunotec's T cell measurement focus.

Emerging players

• DiaSorin: DiaSorin offers the LIAISON QuantiFERON-TB test and other specialty IVD assays, providing a competing TB IGRA solution to clinical laboratories, though with a broader infectious disease and specialty diagnostics portfolio than Oxford Immunotec.

Direct peers

• Qiagen: Qiagen's QuantiFERON-TB Gold Plus is the leading IGRA test for latent TB detection and the primary direct competitor to Oxford Immunotec's T-SPOT.TB in clinical laboratories and TB screening programs globally.
• Cellular Technology Limited (CTL): CTL is a named dominant player in the ELISpot market alongside Oxford Immunotec and Mabtech, providing competing T cell measurement platforms and instruments for immunology research.
• Mabtech: Mabtech is a named dominant player in the ELISpot/FluoroSpot assay market alongside Oxford Immunotec, offering competing T cell immunoassay kits and reagents for research and clinical applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/TBDiagnosis
• YouTubeyoutube.com/channel/UCUqLrqOpUUwhz3UaLn78tVQ
• Facebookfacebook.com/105616676142735
• LinkedInlinkedin.com/company/oxford-immunotec
• Instagraminstagram.com/revvity

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Immunotec